Better Coronavirus Stock: Inovio Pharmaceuticals or Regeneron?
Inovio Pharmaceuticals (NASDAQ: INO) and Regeneron Pharmaceuticals (NASDAQ: REGN) are both deeply involved in making medicines to fight against COVID-19, but the similarities end there. Inovio is a clinical-stage biotech, hoping to utilize its DNA-based vaccine technology to produce an effective inoculation for the coronavirus that will cement the company's long-term survival. In contrast, Regeneron is older, larger, and more established, boasting consistent profitability and a bevy of antibody therapies. Whereas a successful coronavirus program could be revolutionary for Inovio's stock, Regeneron's antibody therapy for COVID-19 may not fundamentally change the company's ability to successfully compete, even if it provides a new source of revenue.
Both stocks have strongly outperformed the market this year, but their future growth prospects are quite different in terms of their level of risk, and they appeal to different types of investors as a result. In my view, Inovio is the preferable stock for investors with a very high tolerance for risk, whereas Regeneron is a better option for most people, especially those who are content with steady long-term growth. Let's take a look at each company to understand this dichotomy a bit more.
Image source: Getty Images.
Source Fool.com
